CD274 and pancreatic neoplasm: This article presents a case report for a patient who had received 3 lines of therapy for recurrent metastatic pancreatic cancer and who then underwent compassionate-use, single-patient Investigational New Drug treatment, initially with a combination of N-803, PD-L1-t-haNK, and aldoxorubicin; followed by ongoing treatment with E-EDV-D682 plus EDV-GC.